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Abstract 
Purpose: To investigate the distribution of plasmid-encoded extended spectrum beta-lacatamases 
(ESBLs) in Lahore, Pakistan using different phenotypic and molecular methods.   
Methods: Escherichia coli and Klebsiella spp were obtained over a period of nineteen months (June 
2007 to December 2008). Both were tested by the double disk synergy test, combined disk test and 
Epsiometer-test (E-test) to evaluate their ability to detect ESBLs. The genotypes of ESBLs were 
analyzed by monoplex polymerase chain reaction (PCR), multiplex PCR, DNA sequencing and 
isoelectric focusing. 
Results: 662 E. coli and 153 Klebsiella spp were analyzed.  Among these isolates, 39.3 % E. coli and 
26.1 % Klebsiella spp were positive for extended spectrum beta-lactamases (ESBLs).71.9 % E. coli and 
79.6 % Klebsiella spp showed minimum inhibitory concentration (MIC) in the range > 32/0.064 = 500 
μl/mL for cetatzidime/cetatzidime + clavulanic acid, while 66.5 %  E. coli and 69.1 % Klebsiella spp 
revealed MIC in the range of > 16/0.016 = 1000 μl/mL for cefotaxime/cefotaxime + clavulanic acid. 
Antibiotic susceptibility testing revealed that imipemem, meropenem and tazocine were the most 
effective in the management of such infections. The most frequent genotype of ESBL was OXA (19.2 
%) for E. coli and SHV (92.5 %) for Klebsiella spp. The highest genotypic combination found was the 
combination of TEM/OXA (44.2 %) for E. coli.   
Conclusion: The resistance of E. coli and Klebsiella spp-producing ESBLs in Pakistan is a serious 
issue, and TEM, OXA and SHV type ESBL were the most common genotypes. Some isolates produced 
two or three genotypes at a time. Multiplex PCR of ESBL may help in early detection as well as 
phenotypic antibiotic therapy of these infections. 
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Antimicrobial resistance is a very serious issue 
all over the world. Pathogenic and opportunistic 
bacteria, which become highly resistant to drugs 
are causing untreatable infections [1]. Such 
bacteria are frequently reported as multidrug 
resistant bacteria (MDR) and some of the MDRs 
produce ESBL.   The incidence and type of ESBL 
producer strains varies according to different 
geographical locations [2,3].  
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lactamase (ESBL) confers resistance to 
cephalosporin group, such as ceftazidime, 
ceftriaxone and others. These enzymes occur in 
genera of the family Enterobacteriaceae for 
example Citrobacter, Enterobacter but 
predominantly present in E. coli and Klebsiella 
species [4]. The successful spread of ESBLs can 
be attributed to the fact that genes encoding for 
ESBLs are often located on self-transmissible or 
mobilizable broad range plasmids [5]. Change in 
the type of ESBL gene determines the activity of 
enzyme, for example if organisms producing 
TEM and SHV type ESBLs, apparent in vitro 
sensitivity to cefepime and to tazobactum is 
changed [6].  These drugs show an inoculum 
effect, with diminished susceptibility as the size 
of the inoculum was increased from 105 to 107 
organisms. Strains having CTX-M–type and 
OXA-type ESBL are resistant to cefepime 
despite the use of standard inoculums [7].   
 
Beta-lactams are important antibiotics in this part 
of world. Only few studies analyzing the extent of 
beta-lactam resistance based on their phenotypic 
features have been conducted. Very little is 
known about the molecular genotyping of 
extended spectrum beta-lactamases. The main 
objective of this work, therefore, was to 
determine beta-lactam resistant phenotypes and 
genotypes of E. coli and K. pneumoniae isolates 




Bacterial isolation and identification 
 
A total of 1018 consecutive and non-duplicate 
lactose fermenting Enterobacteriaceae members 
were collected from Citi lab and Research Center 
during June 2007 to December 2008. All clinical 
specimens were processed according to 
standard operating procedures [8]. Lactose 
fermenting Gram-negative bacteria were 
characterized by colony morphology and 
biochemical tests. Confirmation of identification 
was performed by using API 20E (BioMerieux). 
Data were reported according to guidelines of 
Heath protection agency [9].  
 
Phenotypic detections tests 
 
Phenotypic test includes, double disk synergism 
augmentin (amoxicillin-clavulanate) was used  to 
read the synergism with ceftriaxone (30 µg), 
ceftazidime (30 µg), aztreonam (30 µg), 
cefotaxime (30 µg). Combination disc (CD) test 
was performed using ceftazidime/ceftazidime+ 
clavulanic acid and cefotaxime/cefotaxime+ 
clavulanic acid. Combination disk test was 
considered positive when there was 5 mm 
increase in zone of inhibition as compared to 
non-combination disc. E-test was performed as 
final phenotypic confirmatory test. Detection of 
ESBL was determined based on ratio between 
MIC of ceftazidime and cefotaxime alone or in 
combination with clavulanic acid using E-test 
strips. 
 
Confirmation by using ribotyping  
 
Isolates were also confirmed using 16SrRNA 
sequences. The PCR products were 
subsequently sequenced by Macrogen 
Bioengineering Co., Ltd. The nucleotide 
sequences were analyzed using BLAST 
software, available from the National Center for 
Biotechnology Information (http://www.ncbi.nlm. 
nih.gov). Phylogenetic analysis was performed 
using software seaview. Confirmed isolates were 
stored in trypticase soy broth containing 20 % 
glycerol at -80 °C until use. 
 
Antibiotics susceptibility testing 
 
The antibiotic susceptibility was determined by 
disk diffusion on Mueller-Hinton agar (Bio-Rad, 
Marnes-la-Coquette, France). Multiple antibiotic 
resistances (MAR) of ESBL producing isolates 
according to gender and age groups of patients 
were calculated. The panel used in this study 
consists of 21 antibiotics that belong to three 
major groups of antibiotics according to 
mechanism of action.  Such as antibiotic disks 
containing amikacin 30 μg, ampicillin 10 μg , 
amoxicillin clavulanic acid (20 μg/10 μg) 30 μg, 
carbencilin 100 μg, cephredine 30 μg, 
cefaperazone 75 μg, ciprofloxacin 5 μg, 
gentamicin 10 μg, nitrofurontoin 300 μg, 
imepenem 10 μg, meropenem 10 μg, norfloxacin 
10 μg, cotrimoxazole 25 μg, ceftizoxime 30 μg, 
cefotaxime 30 μg, cefoxitin 30 μg, cetazidime 30 
μg, ceftriaxone 30 μg, cefixime 5 μg, aztreonam 
10 μg, and pipracilin-tazobactam 100/10 μg were 
tested.  
 
Genotyping using PCR and sequence data 
analysis  
 
Colony PCR was performed following Jemima 
[10]. To differentiate blaSHV, blaTEM, blaOXA, the 
published primers were used [11]. Initially, 
singleplex PCR was optimized and then multiplex 
PCR assay of three-primer set was optimized 
(OXA, TEM and SHV genes) and performed. 
ATCC 25922 E. coli (SHV-negative), ATCC 
700603 K. pneumoniae (SHV-positive), ATCC 
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35218 E. coli (TEM-positive) and a strain of E. 
coli (OXA-positive) were used as control strains 
for PCR. Multiplex PCR was developed using 
primer set (OXA, TEM and SHV) in single 
reaction with maximum 25 µL volume of PCR 
mixture. The PCR products were purified using 
Qiagen kit Agarose Gel DNA Purification Kit 
Version 2.0. Subsequently, the amplicons were 
sequenced by Macrogen Bioengineering Co., 
Ltd. The nucleotide and deduced protein 
sequences were compared to those available in 
GenBank. 
 
Isolectric focusing (IEF) 
 
Beta-lactamase was isolated using Massidda 
protocol [12]. Isoelectric focusing was performed 
using 2D gel electrophoresis (BioRad) following 
manufacturer instructions. Spot editing, 
scanning, quantification and evaluation of 
isoelectric points (pI) was calculated by 







Out of 1018 Enterobacteriaceae members, 662 
E. coli, 153 Klebsiella spp, 122 Enterobacter and 
81 Citrobacter were isolated. Clinical samples 
positive for ESBL were as: urine (53 %), blood 
(7.3 %), wound swabs (20.6 %), foley catheter tip 
(10.3 %) and others (8.6 %). Total 300 bacterial 
strains were positive for beta-lactamases, 39.2 % 
E. coli and 26.10 % Klebsiella species were 
found to express ESBLs. Regarding gender 
classification in the case of beta-lactamase 
producing E. coli, females (60 %) had a higher 
incidence as compared to males (40 %). 
Similarly, in case of Klebsiella, more females (55 
%) than males (45 %) were affected. Comparison 
of hospitalized and community acquired 
infections revealed that in both cases > 55 % E. 
coli caused infection following Klebsiella > 45 %. 
Here data of E. coli and Klebsiella was arranged 
according to source of specimens. However, in 
the case of pus swabs, males were more 
infected by Klebsiella (71 %) than E. coli (69 %). 
In blood samples, E. coli showed higher infection 
rates (60 %) as compared to Klebsiella (40 %) for 
male patients. Frequency of infection of E. coli 
from Foley tip was less in males (29 %) than 
females (71 %). In Klebsiella, foley tip infections 
revealed more for females (62 %) than males (38 
%). Other specimens had also high infection rate 




The isolates were further selected based on 
phenotypic detection test from hospitalized and 
community patients following Clinical and 
Laboratory Standard Institute (CLSI) guidelines 
[8].   Ceftazidime had high rate of synergism 
(93.4, 95 %) followed by cefotaxime (88.9, 88.7 
%) aztreonam (86.2, 83.5 %) and ceftriaxone 
(84.5, 83.1 %). In Klebsiella spp highest 
synergism was found with ceftazidime (88.4, 89.1 
%) followed by aztreonam (88.6, 86.2 %), 
cefotaxime (86.7, 89.6 %) and ceftriaxone (84.7, 
88.5 %). Cephalosporin antibiotic ceftazidime, 
cefotaxime alone and combination disc were 
selected for further confirmation. E. coli was 99.2 
% resistant to ceftazidime but was found  98 %  
sensitive, 1.34 % resistant and 0.74 % 
intermediate to ceftazidime+clavulanic acid 
(disc). E. coli was more resistant to cefotaxime 
(99.5 %) and less resistant to cefotaxime+ 
clavulanic acid (disc) (3.84 %).  
 
Cefotaxime+clavulanic acid (disc) increased E. 
coli sensitivity to 96.12 %. Klebsiella spp was 
99.5 % and 99.4 % resistance to ceftazidime and 
cefotaxime, respectively. Combination discs of 
ceftazidime+clavulanic acid and 
cefotaxime+clavulanic acid altered resistance 
against ESBL to 1.36 and 2.12 %, respectively. It 
was observed that 2.8 % E. coli and 1.4 % 
Klebsiella spp had non-determinable > 32/> 4 
(ND), while a majority of ESBL E. coli (71.9 %) 
and Klebsiella (79.6 %) groups fell in the range of 
MIC > 32/0.064 = 500 µl/mL for ceftazidime/ 
ceftazidime+clavulanic. For cefotaxime/ 
cefotaxime+clavulanic (CT/CTL), maximum 
ESBL E.coli (66.5 %) and Klebsiella (69.1 %) 
isolates were in the MIC range of > 16/0.016 = 
1000 µl/mL (Table 1). 
 
Susceptibility of isolates 
 
This panel is designed according to the CLSI 
guidelines [8]. This antibiotic panel is generally 
used in our hospitals and diagnostics labs. Out of 
260 E. coli isolates > 97 % were resistant to 
ampicillin, carbencilin, cephredine, cefuroxime, 
ceftriaxone and ceftazidime. E. coli isolates were 
> 80 % and > 60 % resistant to cefoperazone 
and ceftizoxime respectively. E. coli isolates 
were 50 % resistant to amoxycillin/clavulanic 
acid. 
 
Out of 40 Klebsiella isolates, 100 % were 
resistant to carbencilin, cephredine, cefuroxime 
and   ceftriaxone.   Klebsiella   isolates   >   90 %  
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Table 1: E-test with cetazidime/cetazidime+clavulanic acid (TZ/TZL) and cefotaxime/cefotaxime+clavulanic acid 
(CT/CTL) MIC ratio  
 
Cetazidime/ cetazidime+clavulanic acid (TZ/TZL) MIC(µl/ml) 









E. coli  2.8 71.9 14.6 7.4 1.3 2.0 
Klebsiella 
spp  
1.4 79.6 9.3 4.5 5.2 0.0 
Cefotaxime/ Cefotaxime +clavulanic acid (CT/CTL) MIC(µl/ml) 










E. coli 5.1 66.5 17.6 4.5 2.8 3.5 
Klebsiella 
spp 
1.5 69.1 14.8 8.1 5.3 1.2 
 
resistant to ceftizoxime whereas > 80 % were 
resistant to cefoperazone. > 60 % resistance and 
20 % intermediate sensitivity to amoxycillin/ 
clavulanic acid were seen in Klebsiella isolates. 
E. coli and Klebsiella isolates showed highest 
susceptibility to imepenem followed by 
meropenem and tazocine. There was very rare 
resistance found to meropenum and tazocine (< 
2 %), but no resistance was found to imepenem 
in both types of isolates. Hence, the most 
effective antibiotics that can be used as a 
therapy of choice in both types of isolates were 
imepenem followed by meropenem and tazocine.  
Protein inhibiting drugs, gentamicin and amikacin 
were also used. Klebsiella isolates > 80 % and E. 
coli isolates > 60 % were resistant to gentamicin. 
On the other hand amikacin responded well and 
showed highest activity for E. coli and Klebsiella 
spp. In nucleic acid inhibiting drugs E. coli 
showed > 80 % resistance to ciprofloxacin and 
trimethoprim/sulfamethoxazole, while > 90 % 
resistance to nitrofurontoin and norfloxacin. 
Klebsiella isolates had > 70 % resistance to 






Phylogenetic relation was developed using 
neighbor joining method (NJ method). The tree 
length (sum of branch lengths) was 0.01111 in 
the case of E. coli (Figure 1) and 0.02171 in 
Klebsiella spp (Figure 2); branch lengths are 
proportional to the number of substitutions per 
site. Comparison of two bacterial groups was 
done using Parsimony analysis bootstrap 100 
replicates along with control strains. K-TJW and 
K-ANT used as control Klebsiella spp while K12 
that is used as control E. coli. Sequences were 
submitted to GenBank nucleotide database 
under accession numbers GU594294- 
GU594311.  
 
Figure 1: Phylogenetic tree from 14 aligned 
sequences of 1478 sites, based on the NJ method. 





Figure 2: Phylogenetic tree from 10 aligned Klebsiella 
sequences of 1608 sites, based on the NJ. The tree is 
rooted by outgroup B19 
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Molecular phylogeny of the blaSHV, blaTEM and 
blaOXA beta-lactamase genes 
 
Distributions of TEM, OXA and SHV in bacterial 
isolates were observed (Table 2). Of the 260 
clinical isolates of E. coli suspected to be ESBL 
producers 13.2 %, 19.2 % and 7.6 % 
demonstrated TEM, OXA or SHV-specific PCR 
products respectively. Combination of ESBL 
showed 44.2 %, 3.8 %, 1.5 %, 1.9 % of 
TEM/OXA, TEM/SHV, OXA/SHV, TEM/SHV/ 
OXA-specific products respectively. Sequence 
determination of PCR products obtained from E. 
coli and Klebsiella spp confirmed the identity of 
the genes (Figure 3). Of the 40 clinical isolates of 
Klebsiella spp 92.5 % demonstrated SHV-
specific products, 5 % TEM/OXA and 2.5 % 
TEM/SHV (Table 2).  The nucleotide sequences 
reported in this paper have been submitted to the 
GenBank nucleotide database under accession 
numbers HM063036-HM063040 = SHV, 
HM063041-HM063050 = TEM, HM063051-




Amino acids calculation showed that in SHV 
enzyme most frequent amino acid was Arginine 
following glutamine with average pI 8.11, where 
as in TEM beta-lactamase most frequent amino 
acid was Glutamine following Arginine with 4.47 
pI. In OXA beta-lactamase most frequent amino 
acid was lysine, glutamine, aspartic acid 
following other amino acids. Average pI of OXA 
beta-lactamase calculated was 9.03. 
 
 












E. coli 260 36(13.8) 50(19.2) 20(7.6) 115(44.2) 10(3.8) 4(1.5) 5(1.9) 0(0) 
Klebsiella 
spp 




Figure 3: Parsimony analysis of OXA, TEM and SHV sequences. Analysis of OXA, TEM and SHV aligned 




This research work was conducted because 
there was little available information regarding 
antimicrobial susceptibility and molecular 
characterization of ESBL genotypes of E. coli 
and Klebsiella spp in Pakistan. These members 
of Enterobacteriaceae are well known ESBLs 
producers and are responsible for nosocomial 
and community acquired infections [13]. 
Depending upon the rate of infecting isolates, E. 
coli and Klebsiella were considered as important 
research work. There are many reasons for the 
spread of infections, and these include misuse of 
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antibiotics, animals and hospitals cross infection 
[4]. The prevalence of ESBLs can be different 
based on geographical areas. In Europe, ESBLs 
positivity was 1.3 % of Escherichia coli and 18.4 
% for Klebsiella pneumonia [14]. Several other 
reports are available for other areas like Latin 
America, Asia and also North America [15]. In 
2003 about 30 % ESBL producing E. coli were 
found in Aga Khan University research [12]. 
ESBLs producers were more commonly isolated 
from urinary tract infections (UTI) both in hospital 
and community-acquired infections [16]. In Iran, 
UTI causing ESBL producers were in high 
frequency [17]. Similarly in Japan the increased 
frequency of UTI caused by ESBL producers 
have been reported [18].  
 
When data were analyzed according to gender 
and age groups it depicts that females were 
more infected. This complexity is because of lack 
of medical facilities in rural areas.  High 
frequency of infected patients were observed 
either from young or old age group, this might be 
because of low immunity [13].  Data revealed 
that in Pakistan multidrug resistance was more 
common in the age group of 50+ in both males 
and females [19]. Resistance appeared to be 
correlated with the old age as observed in 
another report [20]. In susceptibility profile 
imepemem, meropenem and tazocine were 
effective against ESBL isolates. Meropenem was 
considered as best option for therapy against 
gram-negative bacilli especially for cephalosporin 
resistant gram-negative bacilli [21]. The good 
activity of imepenem, meropenem and tazocin 
was also previously known [22]. Another work 
that supports this was conducted at King Fahd 
Hospital, Saudi Arabia. However, variability with 
other drugs such as amoxiclar augmentin, 
cefoperazone, ceftizoxime, gentamycin and 
ciprofloxacin was also observed [23].  
 
Our data also suggest that majority of cases are 
positive for ESBLs as earlier reported [24]. 
Overall, phenotypic detection of clinical ESBL 
was 39 % in E. coli and 26 % in Klebsiella spp. In 
previous report, 53 % K. pneumoniae and 44 % 
E. coli were identified as suspected ESBL 
producer [25]. Comparative study of different 
phenotypic techniques revealed that double disc 
synergism (DDS) test was the most economical 
method of detection.  
 
In current study multiplex PCR was developed 
for TEM, OXA and SHV genes. This method of 
diagnosing ESBL is a one-step procedure, which 
is very significant in diagnostics. There are a 
number of studies that showed the significance 
of using multiplex PCR in ESBL. Multiplex PCR 
for SHV and CTXM was developed in another 
study [26].  Multiplex PCR for detection of 
plasmid mediated quinolone resistance ESBL 
has also been developed [27]. The change in the 
antibiotic phenotype pattern in different ESBL, 
clearly differentiated the resistance mechanism 
of beta-alactamase producing isolates. This was 
solved by PCR, which accurately distinguished 
between different types of ESBL genes [28]. On 
sequence similarity analysis, it was found that 
tested isolates had 96 to 100 % similarity to 
sequences of ESBL isolates from China. 
Klebsiella pneumoniae strain B27 (HM063040) 
SHV beta-lactamase producer had 98 % similar 
sequence to clinical Klebsiella pneumoniae strain 
HS94 beta-lactamase [28].  Escherichia coli 
strain B1 (HM063048) TEM-beta-lactamase was 





ESBLs are an increasing problem in healthcare 
facilities, especially in rural areas. Imepemem, 
meropenem and tazocine remain good choices 
for treating infections. Addition of a combination 
disc in routine susceptibility testing gives 
satisfactory results for ESBLs in less time.  TEM, 
OXA and SHV type ESBLs were the most 
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